Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

NCT Number	NCT00412594
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: National Cancer Institute (NCI)
Conditions	Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Enrollment	150 participants
Start Date	2004-06-10
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-11